Reply to the Letter "Reversible Vasoconstriction Syndrome Is a Complication of SARS-CoV-2 Infection/Vaccination Rather than That of Leigh Syndrome"
Intern Med
.
2023 Jul 15;62(14):2159-2160.
doi: 10.2169/internalmedicine.1962-23.
Epub 2023 Apr 21.
Authors
Ayane Ohyama-Tamagake
1
,
Kimihiko Kaneko
1
,
Ryo Itami
2
,
Masatsugu Nakano
3
,
Yasuhiro Namioka
1
,
Rumiko Izumi
1
,
Haruka Sato
4
,
Hideaki Suzuki
4
,
Atsuhito Takeda
5
,
Yukiko Yatsuka
6
,
Yasushi Okazaki
6
7
,
Takaaki Abe
8
,
Kei Murayama
9
,
Naoto Sugeno
1
,
Tatsuro Misu
1
,
Masashi Aoki
1
Affiliations
1
Departments of Neurology, Tohoku University Hospital, Japan.
2
Department of Neurology, Tokyo General Hospital, Japan.
3
Department of Cardiology, Tokyo General Hospital, Japan.
4
Department of Cardiology, Tohoku University Hospital, Japan.
5
Department of Pediatrics, Hokkaido University Hospital, Japan.
6
Diagnostics and Therapeutic of Intractable Diseases, Intractable Disease Research Center, Graduate School of Medicine, Juntendo University, Japan.
7
Laboratory for Comprehensive Genomic Analysis, RIKEN Center for Integrative Medical Sciences, Japan.
8
Department of Clinical Biology and Hormonal Regulation, Tohoku University Hospital, Japan.
9
Department of Metabolism, Chiba Children's Hospital, Japan.
PMID:
37081677
PMCID:
PMC10400391
DOI:
10.2169/internalmedicine.1962-23
No abstract available
Keywords:
Leigh syndrome; Reversible vasoconstriction syndrome.
Publication types
Letter
Comment
MeSH terms
COVID-19* / complications
Humans
Leigh Disease*
SARS-CoV-2
Syndrome
Vaccination
Vasoconstriction